Wednesday - July 08, 2026

Category Archives: Science

Motiqa Cloud Launches Revolutionary $6.29/Month Platform for Unlimited AI-Generated Faceless Video Content Creation

“We’ve democratized content creation by making it possible for anyone to produce viral-worthy videos without the barriers of camera shyness, expensive equipment, or time-consuming editing. At $6.29 per month for unlimited content, we’re removing the financial obstacles that prevent creators … Continue reading →

Muscle-Invasive Bladder Cancer Pipeline Drugs Insights Report 2025: Promising Drugs and MOA Innovations Reshape Future Treatment Approaches | DelveInsight

DelveInsight’s, “Muscle Invasive Bladder Cancer Pipeline Insight 2025” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Muscle Invasive Bladder Cancer pipeline landscape. It covers the Muscle Invasive Bladder Cancer pipeline drug profiles, including clinical and … Continue reading →

Opioid Related Disorder Pipeline Drugs Insights Report 2025: Promising Drugs and MOA Innovations Reshape Future Treatment Approaches | DelveInsight

DelveInsight’s “Opioid Use Disorder Pipeline Insight 2025” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Opioid Use Disorder pipeline landscape. It covers the Opioid Use Disorder pipeline drug profiles, including clinical and nonclinical stage products. … Continue reading →

ShiLai Peptide to Invest $32 Million in State-of-the-Art Peptide Laboratory in Hangzhou

ShiLai Peptide’s CEO, Luo Binhua, said the investment reflects the company’s commitment to a “new science model” that integrates research-driven development, controlled production, and specialized customer support. ShiLai Peptide, a leading provider of high-purity, customizable research peptides, announced plans to … Continue reading →

Crohn’s Disease Outlook Report 2025: Promising Drugs and MOA Innovations Reshape Future Treatment Approaches | DelveInsight

DelveInsight’s, “Crohn’s Disease Pipeline Insight 2025” report provides comprehensive insights about 90+ companies and 90+ pipeline drugs in Crohn’s Disease pipeline landscape. It covers the Crohn’s Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the … Continue reading →

Spinal Cord Injury Pipeline Outlook Report 2025: Promising Drugs and MOA Innovations Reshape Future Treatment Approaches | DelveInsight

DelveInsight’s “Spinal Cord Injury Pipeline Insight 2025” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in the Spinal Cord Injury pipeline landscape. It covers the Spinal Cord Injury pipeline drug profiles, including clinical and nonclinical stage products. … Continue reading →

Triple Negative Breast Cancer Pipeline Outlook Report 2025: Promising Drugs and MOA Innovations Reshape Future Treatment Approaches | DelveInsight

DelveInsight’s “Triple Negative Breast Cancer Pipeline Insight 2025” report provides comprehensive insights about 165+ companies and 170+ pipeline drugs in the Triple Negative Breast Cancer pipeline landscape. It covers the Triple Negative Breast Cancer Pipeline drug profiles, including clinical and … Continue reading →

Stargardt Disease Pipeline Outlook Report 2025: Promising Drugs and MOA Innovations Reshape Future Treatment Approaches | DelveInsight

DelveInsight’s “Stargardt Disease Pipeline Insight 2025” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in the Stargardt Disease pipeline landscape. It covers the Stargardt Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers … Continue reading →

Obesity Pipeline Outlook Report 2025: Promising Drugs and MOA Innovations Reshape Future Treatment Approaches | DelveInsight

DelveInsight’s “Obesity Pipeline Insight 2025” report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in Obesity pipeline landscape. It covers the Obesity pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Obesity therapeutics assessment … Continue reading →

Glucagon-Like Peptide Agonist Pipeline Drugs Insights Report 2025: Promising Drugs and MOA Innovations Reshape Future Treatment Approaches | DelveInsight

DelveInsight’s “Glucagon-Like Peptide Agonist Pipeline Insight 2025” report provides comprehensive insights about 45+ companies and 50+ pipeline drugs in the Glucagon-Like Peptide Agonist pipeline landscape. It covers the Glucagon-Like Peptide Agonist Pipeline drug profiles, including clinical and nonclinical stage products. … Continue reading →